<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330341</url>
  </required_header>
  <id_info>
    <org_study_id>GI-ESTRAGON</org_study_id>
    <nct_id>NCT02330341</nct_id>
  </id_info>
  <brief_title>Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion</brief_title>
  <official_title>Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The term prediabetes has been used to encompass the first alterations on glucose metabolism&#xD;
      such as impaired fasting glucose and glucose intolerance, and its early detection and&#xD;
      treatment could prevent the appearance of diabetes mellitus type 2, a high prevalence disease&#xD;
      worldwide.&#xD;
&#xD;
      Artemisia dracunculus, also known as estragon, has been used in Ayurvedic medicine for the&#xD;
      treatment of diabetes.&#xD;
&#xD;
      Different in vitro and in vivo studies have shown that Artemisia dracunculus increases&#xD;
      insulin signaling and improves insulin sensitivity.&#xD;
&#xD;
      The aim of this study is evaluate the effect of Artemisia dracunculus on glucose intolerance,&#xD;
      insulin sensitivity and insulin secretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial will be carried out in 24&#xD;
      patients with diagnosis of glucose intolerance in accordance with the criteria of American&#xD;
      Diabetes Association (ADA). Glucose, insulin levels, lipid profile, creatinine, uric acid,&#xD;
      and transaminases will be evaluated. An oral glucose tolerance test with 75 g of dextrose&#xD;
      will be held.&#xD;
&#xD;
      12 participants will receive Artemisia dracunculus, 1000 mg, twice per day (2000 mg) before&#xD;
      breakfast and dinner during 3 months. And other 12 patients will receive placebo with the&#xD;
      same prescription.&#xD;
&#xD;
      Area Under de Curve of glucose and insulin will be calculated as well as total insulin&#xD;
      secretion (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and&#xD;
      insulin sensitivity (Matsuda index).&#xD;
&#xD;
      This protocol is approved by a local ethics committee and written informed consent will be&#xD;
      obtained from all volunteers.&#xD;
&#xD;
      Results will be presented as mean and standard deviation. Intra an inter group differences&#xD;
      will be tested using the Wilcoxon signed-ran and Mann Whitney U- test respectively; p&lt;0.05&#xD;
      will be considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a study with two groups of patients with prediabetes. One group received the investigational product (Artemisia Dracunculus) and the other received placebo as control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial Glucose Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Postprandial glucose will be evaluated at baseline and week 12 after a oral glucose tolerance test with enzymatic-colorimetric techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Glucose Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Glycosylated hemoglobin will be evaluated at baseline and week 12 by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Phase of Insulin Secretion at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The first phase of insulin secretion will be calculated at baseline and week 12 with Stumvoll index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Secretion at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Total insulin secretion will be calculated at baseline and week 12 with insulinogenic index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The weight will be measured at baseline and week 12 with a bioimpedance balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Body Mass Index will be calculated at baseline and week 12 with the Quetelet index formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (c-HDL) Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ALT levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>AST levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Uric acid levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Systolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Diastolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Artemisia Dracunculus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Artemisia dracunculus</intervention_name>
    <arm_group_label>Artemisia Dracunculus</arm_group_label>
    <other_name>estragon, tarragon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes&#xD;
&#xD;
          -  Age between 30 and 60 years&#xD;
&#xD;
          -  Glucose intolerance according ADA criteria (blood glucose leve ≥140 mg/dl and ≤199&#xD;
             mg/dL after an oral glucose tolerance test with 75 of oral glucose&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Hypersensibility to Artemisia dracunculus&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid disease&#xD;
&#xD;
          -  Previous treatment for glucose&#xD;
&#xD;
          -  Diabetes diagnosis&#xD;
&#xD;
          -  BMI ≥39.9 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manuel González Ortiz</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <results_first_submitted>August 23, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Researcher Professor</investigator_title>
  </responsible_party>
  <keyword>Glucose Intolerance</keyword>
  <keyword>Artemisia dracunculus</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Artemisia Dracunculus</title>
          <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Artemisia Dracunculus</title>
          <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="7"/>
                    <measurement group_id="B2" value="48.5" spread="7.2"/>
                    <measurement group_id="B3" value="48.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postprandial glucose levels</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="1.3"/>
                    <measurement group_id="B2" value="9.7" spread="1.1"/>
                    <measurement group_id="B3" value="9.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose levels</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="0.8"/>
                    <measurement group_id="B2" value="5.9" spread="0.9"/>
                    <measurement group_id="B3" value="5.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="0.3"/>
                    <measurement group_id="B2" value="5.9" spread="0.4"/>
                    <measurement group_id="B3" value="5.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First phase of insulin secretion</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1057" spread="529"/>
                    <measurement group_id="B2" value="1395" spread="1138"/>
                    <measurement group_id="B3" value="1226" spread="885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total insulin secretion</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="0.2"/>
                    <measurement group_id="B2" value="0.7" spread="0.4"/>
                    <measurement group_id="B3" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="1.3"/>
                    <measurement group_id="B2" value="1.9" spread="1.2"/>
                    <measurement group_id="B3" value="2.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.3" spread="7.7"/>
                    <measurement group_id="B2" value="83" spread="10.2"/>
                    <measurement group_id="B3" value="84.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="2.9"/>
                    <measurement group_id="B2" value="34.1" spread="3.2"/>
                    <measurement group_id="B3" value="33.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="1"/>
                    <measurement group_id="B2" value="5" spread="0.8"/>
                    <measurement group_id="B3" value="5.3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.5"/>
                    <measurement group_id="B2" value="1.7" spread="0.8"/>
                    <measurement group_id="B3" value="2.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein (HDL-c)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.3"/>
                    <measurement group_id="B2" value="1.4" spread="0.4"/>
                    <measurement group_id="B3" value="1.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="25.2"/>
                    <measurement group_id="B2" value="28.8" spread="14.1"/>
                    <measurement group_id="B3" value="36.3" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="17.7"/>
                    <measurement group_id="B2" value="26.4" spread="7.8"/>
                    <measurement group_id="B3" value="29.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.8"/>
                    <measurement group_id="B2" value="65.4" spread="17.7"/>
                    <measurement group_id="B3" value="64.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric Acid</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285.5" spread="113"/>
                    <measurement group_id="B2" value="273.6" spread="58.9"/>
                    <measurement group_id="B3" value="279.6" spread="132.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" spread="11"/>
                    <measurement group_id="B2" value="123" spread="10"/>
                    <measurement group_id="B3" value="121.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="7"/>
                    <measurement group_id="B2" value="75" spread="7"/>
                    <measurement group_id="B3" value="76.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postprandial Glucose Levels at Week 12</title>
        <description>Postprandial glucose will be evaluated at baseline and week 12 after a oral glucose tolerance test with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glucose Levels at Week 12</title>
          <description>Postprandial glucose will be evaluated at baseline and week 12 after a oral glucose tolerance test with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="1.8"/>
                    <measurement group_id="O2" value="9.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of postprandial glucose on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.380</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of postprandial glucose on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.695</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose Levels at Week 12</title>
        <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Levels at Week 12</title>
          <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="0.6"/>
                    <measurement group_id="O2" value="5.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of fasting glucose on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.110</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of fasting glucose on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Hemoglobin at Week 12</title>
        <description>Glycosylated hemoglobin will be evaluated at baseline and week 12 by ELISA</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin at Week 12</title>
          <description>Glycosylated hemoglobin will be evaluated at baseline and week 12 by ELISA</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.4"/>
                    <measurement group_id="O2" value="5.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of glucosylated hemoglobin on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of glucosylated hemoglobin on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.938</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Phase of Insulin Secretion at Week 12</title>
        <description>The first phase of insulin secretion will be calculated at baseline and week 12 with Stumvoll index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion at Week 12</title>
          <description>The first phase of insulin secretion will be calculated at baseline and week 12 with Stumvoll index.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1235" spread="1047"/>
                    <measurement group_id="O2" value="1566" spread="1206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of first phase of insulin secretion on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.733</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of first phase of insulin secretion on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Secretion at Week 12</title>
        <description>Total insulin secretion will be calculated at baseline and week 12 with insulinogenic index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion at Week 12</title>
          <description>Total insulin secretion will be calculated at baseline and week 12 with insulinogenic index.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.2"/>
                    <measurement group_id="O2" value="0.75" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total insulin secretion on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total insulin secretion on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.900</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity at Week 12</title>
        <description>Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity at Week 12</title>
          <description>Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.0"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of insulin sensitivity on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of insulin sensitivity on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.922</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight at Week 12</title>
        <description>The weight will be measured at baseline and week 12 with a bioimpedance balance</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Weight at Week 12</title>
          <description>The weight will be measured at baseline and week 12 with a bioimpedance balance</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="8.2"/>
                    <measurement group_id="O2" value="84.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of weight on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.605</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of weight on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index at Week 12</title>
        <description>Body Mass Index will be calculated at baseline and week 12 with the Quetelet index formula</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index at Week 12</title>
          <description>Body Mass Index will be calculated at baseline and week 12 with the Quetelet index formula</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="2.9"/>
                    <measurement group_id="O2" value="34.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of BMI on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.687</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of BMI on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Week 12</title>
        <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Week 12</title>
          <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.2"/>
                    <measurement group_id="O2" value="5.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total cholesterol on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.339</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total cholesterol on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.246</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides Levels at Week 12</title>
        <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Levels at Week 12</title>
          <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of triglycerides on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.775</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of triglycerides on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.195</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein (c-HDL) Levels at Week 12</title>
        <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (c-HDL) Levels at Week 12</title>
          <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.3"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of HDL-c on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of HDL-c on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) Levels at Week 12</title>
        <description>ALT levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) Levels at Week 12</title>
          <description>ALT levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="17.7"/>
                    <measurement group_id="O2" value="36.7" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of ALT on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of ALT on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) Levels at Week 12</title>
        <description>AST levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) Levels at Week 12</title>
          <description>AST levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="18.1"/>
                    <measurement group_id="O2" value="26.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of AST on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of AST on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.574</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Levels at Week 12</title>
        <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Levels at Week 12</title>
          <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.01" spread="16.8"/>
                    <measurement group_id="O2" value="61.01" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of creatinine on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.480</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of creatinine on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.383</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uric Acid Levels at Week 12</title>
        <description>Uric acid levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Uric Acid Levels at Week 12</title>
          <description>Uric acid levels will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350.9" spread="71.4"/>
                    <measurement group_id="O2" value="309.3" spread="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of uric acid on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of uric acid on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 12</title>
        <description>Systolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 12</title>
          <description>Systolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="11"/>
                    <measurement group_id="O2" value="125" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of systolic blood pressure on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of systolic blood pressure on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 12.</title>
        <description>Diastolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemisia Dracunculus</title>
            <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 12.</title>
          <description>Diastolic blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="8"/>
                    <measurement group_id="O2" value="79" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of diastolic blood pressure on Artemisia Dracunculus group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.170</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of diastolic blood pressure placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.199</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 12 weeks of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Artemisia Dracunculus</title>
          <description>Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Artemisia dracunculus</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. MANUEL GONZALEZ ORTIZ</name_or_title>
      <organization>INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA, UNIVERSITY OF GUADALAJARA</organization>
      <phone>+52 3310585200 ext 34212</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

